Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03763266
Other study ID # 2017308
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 6, 2018
Est. completion date January 20, 2020

Study information

Verified date February 2020
Source Hospital Parc Taulí, Sabadell
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Colonoscopy is the gold-standard for the evaluation of the colorectal mucosa. Colonoscopy quality indicators are the adenoma detection rate, the rate of cecal intubation and the bowel preparation.

The role of diet in preparing for colonoscopy is not fully established. Currently there is not enough evidence available to choice between 3 days of low residue diet versus 1 day.

The research hypothesis is that the low residue diet offers a non-inferior bowel preparation and an improved tolerance.


Recruitment information / eligibility

Status Completed
Enrollment 858
Est. completion date January 20, 2020
Est. primary completion date November 10, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 69 Years
Eligibility Inclusion Criteria:

- Participants in the colorectal cancer screening program that give consent

Exclusion Criteria:

- Contraindication for colonoscopy

Study Design


Intervention

Other:
1 day low residue diet
Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
3 day low residue diet
Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.

Locations

Country Name City State
Spain Hospital Parc Taulí Sabadell Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Hospital Parc Taulí, Sabadell

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bowel preparation Measured with the Boston Bowel Preparation Scale from 0 until 9. 9 represents an excellent preparation. During the colonoscopy
Secondary Diet tolerance Using Likert scale. From 1 to 5, lower is better tolerance. It is reported before entering the endoscopy room. Regarding the 3 or 1 days on low fiber diet depending on which study group is the participant.
Secondary Preparation tolerance Using Likert scale. From 1 to 5, lower is better tolerance. It is reported before entering the endoscopy room. Regarding the 3 or 1 day on bowel preparation depending on which study group is the participant.
Secondary Adenoma detection rate Proportion of colonoscopies with detection of colorectal cancer or adenoma excluding distal hyperplastic up to 2 weeks after colonoscopy depending on pathology department workload.
Secondary Endoscopic diagnosis Final endoscopic diagnosis. For example; normal, diverticulosis, polyps, colorectal cancer, etc. It is assessed during the colonoscopy and will be reported the same day.
Secondary Cecum intubation rate Cecum intubation will be assessed during each colonoscopy if the endoscope reaches the cecum. It will be calculated through study completion, approximately 1 year, for all the study period using all participants having the colonoscopy done
Secondary Intubation time time lapse from the start of the exploration until cecum is reached. it is assessed from the start of the colonoscopy until cecum is reached (1 day)
Secondary Withdrawal time Time lapse between cecum withdrawal the end of the exploration. it is assessed from at the beginning of the withdrawal of the colonoscope until the colonoscopy is finished. (procedure)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Active, not recruiting NCT04989907 - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Active, not recruiting NCT04990258 - A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Completed NCT06216223 - Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients N/A
Enrolling by invitation NCT06015789 - Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
Recruiting NCT06065995 - StoMakker Mobile Application N/A
Recruiting NCT03282786 - Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease N/A
Recruiting NCT06002074 - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases N/A
Recruiting NCT04960826 - Study of an Environmental Risk Factor in Crohn's Disease
Recruiting NCT05413941 - Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease N/A
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT00721812 - A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 Phase 1
Recruiting NCT05809999 - IBD Neoplasia Surveillance RCT N/A
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Recruiting NCT04991324 - Cholecalciferol Comedication in IBD - the 5C-study Phase 3
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Not yet recruiting NCT05043818 - A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT02874365 - Intestinal Stem Cells Characterization N/A